Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hims and Hers Health Inc (HIMS) vs Johnson & Johnson (JNJ) Price & Performance

Hims and Hers Health IncTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Hims and Hers Health Inc vs Johnson & Johnson — how do they compare? Hims and Hers Health Inc trades at $30 (market cap $7.12B), while Johnson & Johnson trades at $260.7 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 87.9× Hims and Hers Health Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.

HIMSJNJ
Market Cap
$7.12B$626.09B
Sector
HealthHealth
52-Week High
$62.76$267.24
52-Week Low
$14.52$172.78
Enterprise Value
$7.82B$654.37B
Volume
6,156,228
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hims and Hers Health Inc

HIMS stock trades at $30.00, down 5.57% amid mixed Q2 2026 results. Revenue growth remains strong, with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a wider-than-expected quarterly loss. Technical indicators are neutral to bearish, with the price near key support at $30. Recent news highlights an FTC investigation and class-action lawsuits as headwinds.

The investment outlook is cautious. Growth prospects from subscriber gains and AI integration are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33.00 price target, suggesting limited near-term upside amid profitability concerns and negative free cash flow trends.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ